Muslim forum names scholarship after Narendra Modi

Bengaluru, May 27: A yet incomplete state-wide survey has revealed that there are over 53.99 lakh households vulnerable to the infection in Karnataka. The survey is being conducted by the government to find COVID-19 vulnerable population particularly with comorbidities and cases like SARI and ILI.

The survey, which is 67.16% complete so far, finds 1.37 lakh households across Karnataka have people with comorbid conditions, excluding a further 13,341 households with symptoms of Influenza Like Illness (ILI), Severe Acute Respiratory Infection (SARI) and Covid-19.

Over 48 lakh households have senior citizens, who on account of their age are at highest risk of death from the disease.

Munish Moudgil, Director of the State COVID War Room, clarified that households could have multiple types of vulnerable people. According to the survey data (which is dated May 26), Kalaburagi and Bengaluru Urban have the highest cases of SARI, ILI with 1,902 households and 1,703 households respectively, although these numbers are likely to rise, as the survey is still incomplete in these districts. 

A BBMP source said that 68% of the survey has been completed in the city, but the data has not been logged yet. The number of SARI/ILI cases is next highest in Shivamogga with 1,217 households, Mysuru with 1,200 and Davangere with 1,178.

The government regards SARI and ILI as indicators of coronavirus and on April 17, had passed an order instructing healthcare workers to test people with these conditions for the coronavirus. Consequently, 51 COVID-19 cases were discovered by testing people with these symptoms.

Belagavi, meantime, has reported the highest incidents of households with comorbid conditions with 12,427 identified so far, followed by Mandya with 9,289, Kalaburagi with 8,311, Shivamogga with 8,140 and Bengaluru Urban with 7,562. Importantly, 3,45,443 vulnerable people have been identified in Bengaluru Urban within 28.26% of data logged in so far.

Udupi, Apr 9: Deputy Commissioner G. Jagadeesha said that criminal cases would be booked against owners of houses and sheds who were collecting rent from those, including workers, staying in rented houses.

In a statement issued here on Wednesday, Mr Jagadeesha said that to prevent the spread of COVID-19, restrictions had been imposed throughout the district under Section 144 (3) of the Criminal Procedure Code.

The administration had through an earlier order made it clear that house owners and shed owners should not collect rent from their tenants and workers for March and April.

But the administration had received complaints that some house owners and shed owners were collecting rent despite the order.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.